AKT-AMPKα-mTOR-dependent HIF-1α Activation is a New Therapeutic Target for Cancer Treatment: A Novel Approach to Repositioning the Antidiabetic Drug Sitagliptin for the Management of Hepatocellular Carcinoma

• Main Authors: Eslam E. Abd El-Fattah (Author), Sameh Saber (Author), Mahmoud E. Youssef (Author), Hanan Eissa (Author), Eman El-Ahwany (Author), Noha A. Amin (Author), Mohammed Alqarni (Author), Gaber El-Saber Batiha (Author), Ahmad J. Obaidullah (Author), Mohamed M.Y. Kaddah (Author), Ahmed Gaafar Ahmed Gaafar (Author), Ahmed A.E. Mourad (Author), Gomaa Mostafa-Hedeab (Author), Amir Mohamed Abdelhamid (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

HIF-1α is a key factor promoting the development of hepatocellular carcinoma (HCC). As well, AKT-AMPKα-mTOR signaling is a promising target for cancer therapy. Yet, the AKT-AMPKα-mTOR-dependent activation of HIF-1α has not been studied in livers with HCC. In addition, the mechanisms underlying the p...